• Myeloid, atypical chronic myelogenic leukemia, chronic neutrophilic leukemia, NGS panel
• AML / Myeloid, acute myeloid leukemia - prognostic panel 1, NGS
• AML / Myeloid, acute myeloid leukemia - panel 2 other therapeutic options, NGA panel
• AML / Myeloid, acute myeloid leukemia - panel 3 sensitive for sAML and prognostic, NGS panel

• Lymphoid, chronic lymphocytic leukemia, prognostic NGS panel
• BCR-ABL t(9;22)
  • BCR-ABL t(9;22), Philadelphia-Translocation for CML and ALL, qualitative
  • BCR-ABL t(9;22), Philadelphia-Translocation for CML and ALL, quantitative
  • BCR-ABL, Sequencing of ABL for t(9;22) to verify secondary TKI-Resistance

• CBFB-MYH11 inv(16)
• CBFB-MYH11 inv(16) fusion type A
• CCAAT / enhancer-binding protein, alpha (CEBPA)
• Chronic neutrophilia caused by heterozygous mutation in the CSF3R gene
• Chronic lymphoblastic leukemia (B cell): prognostic markers IGHV, TP53, SF3B1, NOTCH1
• Myeloid, chronic myelomonocytic leukemia: core panel diagnostic and prognostic, NGS

• Eosinophiliediagnostik
• Erythrocytosis, isolated
• ETV6-PDGFRB fusion gene

• FIP1L1/PDGFRA fusion gene (microdeletion 4q12)
• FLT3 gene: FMS-related tyrosine kinase 3, qualitative

• IGHV-Status as prognosis marker for CLL

• JAK2 mutations V617F and Exon 12-15

• KIT mutations verification in the case of AML
• Immunoglobulin heavy chains variable gene cluster, IGHV
• Clonality verification T-cell receptor, beta and gamma chain (TCRB, TCRG)

• Large granular lymphocytic leukemia, T-LGL and NK-LGL: STAT3 mutations
• Lymphoid, unclear disease entity - NGS panel

• Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, AHN panel, NGS
• Myeloid, myeloproliferative neoplasia, systemic mastocytosis SM, prognostic panel small, NGS panel
• Myeloid, myelodysplastic syndrome with isolated del(5q), markers with therapeutic relevance, NGS panel
• Myeloid, myelodysplastic/myeloproliferative neoplasms, MDS / MPN overlap, NGS panel
• Myeloid, myelodysplastic syndrome MDS diagnostic, NGS panel
• Myeloid, myelodysplastic syndrome MDS - prognostic markers, NGS panel
• Myeloid, myelodysplastic syndrome MDS, markers with therapeutic relevance, NGS panel
• MLL / MLL-PTD (partial Tandem duplication)
• MLL-MLLT2 (AF4) Transcripts(4;11)(q21;q23) in the case of ALL
• MPL mutations in the case of thrombocytopenia or myelofibrosis
• Myeloid, myeloproliferative neoplasia, NGS panel 1
• Myeloid, myeloproliferative neoplasia, extended diagnosis panel, NGS panel 2
• Myeloid, myeloproliferative neoplasia, extended prognostic panel, NGS
• Multiplex aberration screening, 28 markers (for AML, ALL, CML)
• Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel according to MIPSS70 or MIPSS70 plus, NGS panel
• Myeloid, myeloproliferative neoplasia, myelofibrosis prognostic panel MIPSS70 or MIPSS70 plus extended, NGS panel
• Myeloid, unclear disease entity, NGS panel
• Myeloid neoplasias (AML, CMML, MDS, MPN) - mutation screening

• NPM1 gene for nucleophosmin, qualitative
• NPM1 gene for nucleophosmin, quantitative
• NRAS gene

• PML/RAR alpha t(15;17)
• PML/RAR alpha t(15;17) quantitative, L type (BCR1), S type (BCR3) and V type (BCR2)
• AA / myeloid, Aplastic Anemia - prognostic and therapeutic markers, NGS panel
• Myeloid, myeloproliferative neoplasia, polycythemia vera - prognostic panel, NGS
• Polycythemia vera (PV)

• RUNX1 mutation verification
• RUNX1-RUNX1T1 t(8;21) / AML1-ETO t(8;21)
• RUNX1-RUNX1T1 t(8;21)(q22;q22), quantitative / AML1-ETO

• SETBP1 combined with atypical CML, CNL, CMML

• Thrombocythemia, essential
• Myeloid, myeloproliferative neoplasia, essential thrombocythemia ET - prognostic panel, NGS
• Thrombocythemia, familial (hereditary disposition)
• TP53 point mutation

• ZNF198-FGFR1 Fusion gene